Criteria for malignancy in gastrointestinal endocrine tumors

被引:6
作者
Bordi, Cesare [1 ]
D'Adda, Tiziana [1 ]
Azzoni, Cinzia [1 ]
Pizzi, Silvia [1 ]
Bottarelli, Lorena [1 ]
Mormandi, Francesca [1 ]
Antonetti, Tornmaso [1 ]
Luong, Tu Vinh [1 ]
Rindi, Guido [1 ]
机构
[1] Univ Parma, Dept Pathol & Lab Med, Sect Anat Pathol, I-43100 Parma, Italy
关键词
WHO classification; prognosis; well-differentiated endocrine carcinoma; poorly differentiated endocrine carcinoma; Ki-67; foregut endocrine tumors; midgut endocrine tumors;
D O I
10.1385/EP:17:2:119
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In contrast with the large amount of data generated from endocrine tumors of the pancreas, sparse and mostly unconfirmed data are available on the criteria for the assessment of malignancy risk and patient outcome in endocrine tumors of the gastrointestinal tract. In these conditions the 2000 WHO classification with its standardized scheme of pathologic report constitutes a framework facilitating the assessment of tumor malignancy and has been regarded as useful for clinical purposes, providing the basis for proper management of the patients and for the design of treatment protocols. The classification is based on a combination of pathological and clinical features with parameters specific for each organ in which the endocrine tumors originate. Three main categories, one further subdivided into two subgroups, are considered: (1) well-differentiated endocrine tumors, further subdivided into tumors with benign and with uncertain behavior; (2) well-differentiated endocrine carcinomas, low grade; and (3) poorly differentiated endocrine carcinomas, high grade. In this review the differential tumor characteristics between the different categories are summarized. Moreover, the relevance of additional features with respect to tumor prognostication, chiefly the Ki-67 proliferation index and malignancy-associated genetic changes, is discussed with emphasis on the discrepancies emerging between tumors of foregut and of midgut origin.
引用
收藏
页码:119 / 129
页数:11
相关论文
共 56 条
[1]   Deletion at 3p25.3-p23 is frequently encountered in endocrine pancreatic tumours and is associated with metastatic progression [J].
Barghom, A ;
Komminoth, P ;
Bachmann, D ;
Rütimann, K ;
Saremaslani, P ;
Muletta-Feurer, S ;
Perren, A ;
Roth, J ;
Heitz, PU ;
Speel, EJM .
JOURNAL OF PATHOLOGY, 2001, 194 (04) :451-458
[2]   Putative tumor suppressor loci at 6q22 and 6q23-q24 are involved in the malignant progression of sporadic endocrine pancreatic tumors [J].
Barghorn, A ;
Speel, EJM ;
Farspour, B ;
Saremaslani, P ;
Schmid, S ;
Perren, A ;
Roth, J ;
Heitz, PU ;
Komminoth, P .
AMERICAN JOURNAL OF PATHOLOGY, 2001, 158 (06) :1903-1911
[3]  
Beghelli S, 1998, J PATHOL, V186, P41, DOI 10.1002/(SICI)1096-9896(199809)186:1<41::AID-PATH172>3.0.CO
[4]  
2-L
[5]   EXPRESSION OF GLYCOPROTEIN HORMONE ALPHA-SUBUNIT BY ENDOCRINE-CELLS OF THE OXYNTIC MUCOSA IS ASSOCIATED WITH HYPERGASTRINEMIA [J].
BORDI, C ;
PILATO, FP ;
BERTELE, A ;
DADDA, T ;
MISSALE, G .
HUMAN PATHOLOGY, 1988, 19 (05) :580-585
[6]   COMPARATIVE-STUDY OF 7 NEURO-ENDOCRINE MARKERS IN PANCREATIC ENDOCRINE TUMORS [J].
BORDI, C ;
PILATO, FP ;
DADDA, T .
VIRCHOWS ARCHIV A-PATHOLOGICAL ANATOMY AND HISTOPATHOLOGY, 1988, 413 (05) :387-398
[7]   Gastrointestinal endocrine tumors: Recent developments [J].
Bordi, C ;
D'Adda, T ;
Azzoni, C ;
Canavese, G ;
Brandi, ML .
ENDOCRINE PATHOLOGY, 1998, 9 (02) :99-115
[8]  
Bordi C, 1998, YALE J BIOL MED, V71, P273
[9]  
Bordi C, 1995, AM J SURG PATHOL, V19, P8
[10]  
BORDI C, 2002, CURR DIAGN PATHOL, V8, P421